Scott Gottlieb

This article is about the American physician. For the drummer, see Scott Gottlieb (musician).

Scott Gottlieb
Gottlieb in 2017
23rd Commissioner of Food and Drugs
In office
May 11, 2017 – April 5, 2019
PresidentDonald Trump
DeputyAnna Abram
Preceded byRobert Califf
Succeeded byNorman Sharpless
Personal details
Born (1972-06-11) June 11, 1972 (age 52)
East Brunswick, New Jersey, U.S.
Political partyRepublican
EducationWesleyan University (BA)
Mount Sinai School of Medicine (MD)

Scott Gottlieb (born June 11, 1972) is an American physician, investor, and author who served as the 23rd commissioner of the Food and Drug Administration (FDA) from May 2017 until April 2019. He is presently a senior fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA),[1][2] a member of the board of directors of drug maker Pfizer, Inc[3] and gene sequencing company Illumina, Inc.[4] and a contributor to cable financial news network CNBC and the CBS News program Face the Nation.[5] An elected member of the National Academy of Medicine, Gottlieb is the author of The New York Times best selling book Uncontrolled Spread[6] on the COVID-19 pandemic and the national security vulnerabilities that it revealed. His forthcoming book, The Miracle Century: Making Sense of the Cell Therapy Revolution, traces the scientific achievements that propelled progress in cell therapies.

Before becoming FDA Commissioner, he was a Clinical Assistant Professor at New York University Grossman School of Medicine, the FDA's Deputy Commissioner for Medical and Scientific Affairs, a venture partner with New Enterprise Associates (NEA) from 2007 to 2017, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare & Medicaid Services and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017, prior to joining the FDA as Commissioner in May 2017.

  1. ^ Mack, Heather (May 22, 2019). "Former FDA Commissioner Gottlieb Returns to NEA as Venture Investor". The Wall Street Journal. Retrieved June 2, 2019.
  2. ^ New Enterprise Associates, Inc. (May 22, 2019). "NEA Welcomes Scott Gottlieb, M.D., As Special Partner". PR Newswire (Press release). Chevy Chase, MD: Cision. Retrieved January 17, 2023.
  3. ^ Feinstein, Clarrie (June 28, 2019). "Ex-FDA chief Scott Gottlieb just joined the board of $240 billion drugmaker Pfizer". Business Insider. Retrieved July 5, 2019.
  4. ^ "Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina's Board of Directors". investor.illumina.com. Retrieved February 26, 2021.
  5. ^ "How a Coronavirus Expert Shook Up CBS' 'Face the Nation'". Variety. Retrieved August 10, 2021.
  6. ^ Ward, Myah (June 4, 2021). "Here come the pandemic memoirs". POLITICO. Retrieved August 26, 2021.